<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132783">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01869478</url>
  </required_header>
  <id_info>
    <org_study_id>12-002496</org_study_id>
    <nct_id>NCT01869478</nct_id>
  </id_info>
  <brief_title>Feasibility Study of IV rtPA vs. Primary Endovascular Therapy for Acute Ischemic Stroke</brief_title>
  <acronym>EARLY</acronym>
  <official_title>Endovascular Arterial Reperfusion vs. Intravenous ThromboLYsis for Acute Ischemic Stroke (EARLY): A Randomized Pilot Study of Ultra-early (&amp;lt;2 Hours) and Early (2-4.5 Hours) Reperfusion Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial will be the first step toward direct comparison of delivery of endovascular
      reperfusion therapy to intravenous rt-PA in a time-to-treatment framework shown as most
      effective by the NINDS rt-PA Stroke Trial.   A randomized trial is justified for the
      following reasons:  1) The high rate of death and disability associated with ischemic stroke
      despite treatment with intravenous rt-PA mandates critical analysis of alternate therapies
      with therapeutic potential,  2) endovascular treatment for acute ischemic stroke is
      expanding in North America without compelling evidence of safety and efficacy from
      well-designed clinical trials, 3) critical cost-effectiveness analysis cannot be done
      without acquiring pertinent outcomes data from controlled studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recanalization rate of primary intracranial occlusion</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The degree of recanalization (none, partial, complete) will be assessed in a blinded fashion on the 24-hour CTA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Functional outcome at 90-days will be assessed with the modified Rankin Scale (mRS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Stroke</condition>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Intravenous Thrombolysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.9mg/kg intravenous rt-PA (max dose 90mg) - 10% administered as a bolus over 1 minute and the remainder infused over 60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endovascular Arterial Reperfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapeutic options will include mechanical thrombectomy/clot disruption (Penumbra aspiration system, Solitaire device, and/or Reflex catheter) and/or intracranial stent deployment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Thrombolysis</intervention_name>
    <arm_group_label>Intravenous Thrombolysis</arm_group_label>
    <other_name>Altelplase, rtPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular Arterial Reperfusion</intervention_name>
    <arm_group_label>Endovascular Arterial Reperfusion</arm_group_label>
    <other_name>Penumbra, Solitaire</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Definite or probable ischemic stroke

          -  CT angiographic (CTA) evidence of intracranial vascular occlusion (internal carotid,
             middle cerebral - M1 or M2 divisions, anterior cerebral, posterior cerebral, or
             basilar artery) within 3.5 hours of symptom onset

          -  Able to receive assigned treatment within 4.5 hours of symptom onset

          -  Written informed consent from patient or surrogate, if unable to provide consent

        Exclusion Criteria:

          -  CT evidence of early infarction in &gt;1/3 of middle cerebral artery distribution

          -  Blood pressure &gt; 185/110 mmHg refractory to anti-hypertensive therapy

          -  History of intracranial hemorrhage

          -  History of ischemic stroke within past 3 months

          -  History of major surgical procedure within past 14 days

          -  Gastrointestinal or genitourinary bleeding within past 14 days

          -  Glucose &lt;50 or &gt;400mg/dL

          -  Platelet count &lt;100,000

          -  INR ≥ 1.7

          -  Known history of bleeding diathesis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin M Barrett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sothear Luke, MPH</last_name>
      <email>luke.sothear@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 5, 2014</lastchanged_date>
  <firstreceived_date>June 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Kevin M. Barrett, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
